KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Research & Development (2016 - 2025)

NovoCure's Research & Development history spans 11 years, with the latest figure at $60.9 million for Q4 2025.

  • For Q4 2025, Research & Development rose 18.93% year-over-year to $60.9 million; the TTM value through Dec 2025 reached $224.5 million, up 7.11%, while the annual FY2025 figure was $224.5 million, 7.11% up from the prior year.
  • Research & Development for Q4 2025 was $60.9 million at NovoCure, up from $54.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $60.9 million in Q4 2025 and bottomed at $42.2 million in Q1 2022.
  • The 5-year median for Research & Development is $53.9 million (2025), against an average of $53.2 million.
  • The largest annual shift saw Research & Development soared 81.69% in 2021 before it decreased 13.58% in 2024.
  • A 5-year view of Research & Development shows it stood at $56.9 million in 2021, then decreased by 3.71% to $54.8 million in 2022, then decreased by 0.93% to $54.3 million in 2023, then decreased by 5.7% to $51.2 million in 2024, then rose by 18.93% to $60.9 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Research & Development are $60.9 million (Q4 2025), $54.0 million (Q3 2025), and $55.8 million (Q2 2025).